Core Viewpoint - WuXi AppTec's CAR-T product, Benauda, has passed expert review for inclusion in the 2025 National Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory, signaling a positive regulatory shift towards improving access to advanced therapies [1] Group 1: Company Updates - WuXi AppTec's stock rose nearly 7% during trading, closing up 6.1% at HKD 4.35, with a trading volume of HKD 7.2867 million [1] - The company has confirmed that its CAR-T product, Benauda, is included in over 70 commercial health insurance products [1] - WuXi AppTec plans to actively participate in the application process for the 2025 medical insurance and commercial insurance innovative drug directories [1] Group 2: Industry Insights - The National Healthcare Security Administration has completed the expert review for five CAR-T drugs, including Benauda, which is seen as a positive signal for the accessibility of cutting-edge therapies [1] - CAR-T therapies have not yet entered the basic medical insurance directory due to their high pricing, often exceeding one million yuan per injection [1] - The current payment structure for CAR-T therapies is diverse, primarily relying on commercial health insurance, supplemented by special disease insurance, financial installment plans, and various assistance programs [1]
港股异动 | 药明巨诺-B(02126)盘中涨近7% CAR-T产品集体通过专家评审 公司积极准备医保申报工作